CJC-1295 (no DAC)

Early human Growth Hormone 3 sources

CJC-1295 (no DAC), also known as Modified GRF 1-29, is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). It stimulates the pituitary gland to release growth hormone in a pulsatile manner, mimicking the body's natural physiological rhythms. Research indicates it can increase GH and IGF-1 levels, supporting muscle growth, fat loss, and recovery.

01Dosing reference

Amount

100 mcg per injection

Frequency

1-3 times daily (often morning, post-workout, and/or before bed)

Cycle

5 days on, 2 days off; typically for 8-12 weeks

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Receptor Binding

Binds to the GHRH receptors located in the anterior pituitary gland.

Hormone Stimulation

Triggers the pulsatile release of endogenous Growth Hormone (GH) into the bloodstream.

Systemic Effects

Elevated GH leads to increased production of Insulin-like Growth Factor 1 (IGF-1) in the liver, promoting cellular repair, muscle growth, and lipolysis.

03Human evidence

Increases in circulating Growth Hormone and IGF-1 levels.

Observed in clinical studies evaluating GHRH analogues in healthy adults, showing significant but transient spikes in GH.

Preservation of natural pulsatile GH release.

Unlike long-acting analogues, the short half-life allows the pituitary to recover, reducing the risk of receptor downregulation.

04Preclinical evidence

Enhanced muscle hypertrophy and fat metabolism.

Animal models demonstrated improved body composition when administered GHRH analogues over several weeks.

Synergistic effects when combined with GHRPs.

In vivo studies showed that co-administration with a Growth Hormone Releasing Peptide (like Ipamorelin) exponentially increased GH output compared to either compound alone.

05What is known vs. unknown

Reasonably established

Has a short half-life of approximately 30 minutes, mimicking natural GH pulses.
Composed of the first 29 amino acids of endogenous GHRH with modifications to increase stability.
Often administered multiple times a day or paired with a GHRP for maximum efficacy.
Does not contain the Drug Affinity Complex (DAC), which prevents continuous GH elevation.

Unknowns & limits

Long-term safety and potential effects on pituitary gland function with extended use.
Optimal dosing frequency for specific therapeutic outcomes like anti-aging versus injury recovery.
Individual variability in GH response based on age and baseline hormone levels.

06Safety & regulatory context

Regulatory statusIn research settings, CJC-1295 (no DAC) is generally well-tolerated. Common side effects include temporary flushing, a 'head rush' feeling immediately after injection, mild water retention, and injection site reactions. Because it mimics natural pulsatile release, it is considered to have a lower risk of pituitary desensitization compared to long-acting GH secretagogues. It is not FDA-approved for human consumption and is classified as an investigational research chemical.

07Compared with CJC-1295 (with DAC)

CJC-1295 (no DAC) vs. CJC-1295 (with DAC)

Key difference

CJC-1295 with DAC has a half-life of several days causing continuous GH release, whereas no DAC has a 30-minute half-life causing a pulsatile release.

When researchers discuss each

Researchers prefer 'no DAC' for mimicking natural physiological GH pulses and avoiding pituitary fatigue, while 'with DAC' is studied for convenience of infrequent dosing.

08Glossary

GHRH

Growth Hormone-Releasing Hormone, a natural peptide that stimulates the pituitary gland to produce and release growth hormone.

Pulsatile Release

The secretion of hormones in short bursts or pulses, rather than a continuous steady stream, which is how the body naturally operates.

Half-life

The time required for the concentration of a substance in the body to reduce by half.

Pituitary Gland

A small gland at the base of the brain that produces and regulates various hormones, including growth hormone.

09Knowledge check

Q1What is the primary advantage of CJC-1295 (no DAC) over its DAC-containing counterpart?

Q2Which gland does CJC-1295 (no DAC) target to stimulate hormone release?

Q3Which documented limitation of the evidence about CJC-1295 (no DAC) is explicitly noted in the dossier?

Q4According to the dossier, why do researchers often prefer CJC-1295 (no DAC) instead of the DAC-containing form in studies focused on physiological GH regulation?

Q5Which statement about the safety or regulatory status of CJC-1295 (no DAC) is supported by the dossier?

10Sources

More in Growth Hormone

See all

Sermorelin

Growth Hormone

FDA-approved context

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to naturally produce and release human growth hormone (hGH), making it a subject of research for age-related growth hormone decline, body composition, and vitality.

200-500 mcg/day

Tesamorelin

Growth Hormone

FDA-approved context

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete growth hormone. It is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy and is being researched for potential cognitive benefits.

2 mg/day

Hexarelin

Growth Hormone

Human clinical

Hexarelin is a potent, synthetic hexapeptide and growth hormone secretagogue (GHS) that stimulates the release of growth hormone. Research indicates it is one of the strongest GH-releasing peptides available, offering potential benefits for muscle growth, fat loss, and cardiovascular health without significantly increasing appetite.

100-200 mcg per dose

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.